NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Chinnadurai S, Snyder K, Sathe N, et al. Diagnosis and Management of Infantile Hemangioma [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2016 Jan. (Comparative Effectiveness Reviews, No. 168.)
Table H-5Zyclara® Adverse Event Data
| Zyclara® 2.5% (n=160) | Zyclara® 3.75% (n=160) | |
|---|---|---|
| Adverse Events reported in ≥2% of Patients | ||
| Headache | 3(2%) | 10(6%) |
| Application site pruritus | 6(4%) | 7(4%) |
| Fatigue | 2(1%) | 7(4%) |
| Nausea | 1(1%) | 6(4%) |
| Influenza like illness | 6(4%) | 1(<1%) |
| Application site irritation | 4(3%) | 5(3%) |
| Pyrexia | 0 | 5(3%) |
| Anorexia | 0 | 4(3%) |
| Dizziness | 1(<1%) | 4(3%) |
| Herpes simplex | 0 | 4(3%) |
| Application site pain | 2(1%) | 5(3%) |
| Lymphadenopathy | 4(3%) | 3(2%) |
| Oral herpes | 4(3%) | 0 |
| Arthralgia | 4(3%) | 2(1%) |
| Cheilitis | 3(2%) | 0 |
| Diarrhea | 2(1%) | 3(2%) |
| Local Skin Reactions | ||
| Erythema (Mild, moderate or severe) | 96% | 96% |
| Severe erythema | 14% | 25% |
| Scabbing/Crusting (mild, moderate or severe) | 84% | 93% |
| Severe scabbing/crusting | 9% | 14% |
| Edema (mild, moderate or severe) | 63% | 75% |
| Severe edema | 4% | 6% |
| Erosion/Ulceration (mild, moderate or severe) | 52% | 62% |
| Severe erosion/ulceration | 9% | 11% |
| Exudate (mild, moderate or severe) | 39% | 51% |
| Severe Exudate | 1% | 6% |
| Flaking/Scaling/Dryness (mild, moderate or severe): | 88% | 91% |
| Severe Flaking/Scaling/Dryness | 4% | 8% |
- Table H-5, Zyclara® Adverse Event Data - Diagnosis and Management of Infantile H...Table H-5, Zyclara® Adverse Event Data - Diagnosis and Management of Infantile Hemangioma
- Mus musculus CHMP family, member 7 (Chmp7), mRNAMus musculus CHMP family, member 7 (Chmp7), mRNAgi|141801415|ref|NM_134078.3|Nucleotide
Your browsing activity is empty.
Activity recording is turned off.
See more...